NEW YORK (GenomeWeb News) – Biocius Life Sciences said today that it is now an independent operating company after completing its spin out from parent company Biotrove, which was recently acquired by Life Technologies.

Biocius said that it now holds all of the intellectual property related to the RapidFire mass spectrometry platform formerly owned by Biotrove; and that it will employ all former employees of Biotrove's RapidFire business unit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.